Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer - PubMed (original) (raw)
. 2007 Nov;21(13):3763-70.
doi: 10.1096/fj.07-8832com. Epub 2007 Jun 22.
Affiliations
- PMID: 17586727
- DOI: 10.1096/fj.07-8832com
Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer
A Kate Sasser et al. FASEB J. 2007 Nov.
Abstract
Bone is the primary anatomical site of breast cancer metastasis, and bone metastasis is associated with increased morbidity and mortality. Mesenchymal stem cells (MSC) are a predominant fibroblast cell population within the bone marrow, and metastatic breast cancer cells that seed within bone would predictably encounter MSC or their soluble factors. Therefore, we examined the impact of primary human MSC on a panel of estrogen receptor-alpha (ERalpha)-positive (MCF-7, T47D, BT474, and ZR-75-1) and ERalpha-negative (MDA-MB-231 and MDA-MB-468) human breast tumor cell lines. All ERalpha-positive breast tumor cell lines displayed low basal activation of signal transducer and activator of transcription 3 (STAT3) until exposed to MSC, which induced chronic phosphorylation of STAT3 on tyrosine-705. Paracrine IL-6 was found to be the principal mediator of STAT3 phosphorylation in coculture studies, and MSC induction of STAT3 phosphorylation was lost when IL-6 was depleted from MSC conditioned media or the IL-6 receptor was blocked on tumor cells. Enhanced tumor cell growth rates were observed in the ERalpha-positive mammary tumor cell line MCF-7 after paracrine and autocrine IL-6 exposure, where MCF-7 growth rates were enhanced by >2-fold when cocultured with MSC in vitro and even more pronounced in vivo with autocrine IL-6 production.
Similar articles
- Human bone marrow stromal cells enhance breast cancer cell growth rates in a cell line-dependent manner when evaluated in 3D tumor environments.
Sasser AK, Mundy BL, Smith KM, Studebaker AW, Axel AE, Haidet AM, Fernandez SA, Hall BM. Sasser AK, et al. Cancer Lett. 2007 Sep 8;254(2):255-64. doi: 10.1016/j.canlet.2007.03.012. Epub 2007 Apr 27. Cancer Lett. 2007. PMID: 17467167 - [Angiogenic effect of interleukin-8 in breast cancer and its association with estrogen receptor].
Lin Y, Wang SM, Huang RP. Lin Y, et al. Zhonghua Yi Xue Za Zhi. 2005 Jun 1;85(20):1419-23. Zhonghua Yi Xue Za Zhi. 2005. PMID: 16029657 Chinese. - Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
Bendre MS, Margulies AG, Walser B, Akel NS, Bhattacharrya S, Skinner RA, Swain F, Ramani V, Mohammad KS, Wessner LL, Martinez A, Guise TA, Chirgwin JM, Gaddy D, Suva LJ. Bendre MS, et al. Cancer Res. 2005 Dec 1;65(23):11001-9. doi: 10.1158/0008-5472.CAN-05-2630. Cancer Res. 2005. PMID: 16322249 - The role of intratumoral and systemic IL-6 in breast cancer.
Dethlefsen C, Højfeldt G, Hojman P. Dethlefsen C, et al. Breast Cancer Res Treat. 2013 Apr;138(3):657-64. doi: 10.1007/s10549-013-2488-z. Epub 2013 Mar 27. Breast Cancer Res Treat. 2013. PMID: 23532539 Review.
Cited by
- Obesity-Associated Breast Cancer: Analysis of Risk Factors and Current Clinical Evaluation.
Engin A. Engin A. Adv Exp Med Biol. 2024;1460:767-819. doi: 10.1007/978-3-031-63657-8_26. Adv Exp Med Biol. 2024. PMID: 39287872 Review. - Investigation of the immunological effects of escitalopram oxalate in the breast cancer co-culture model.
Biriz N, Canturk Z. Biriz N, et al. Asian Biomed (Res Rev News). 2024 Jun 28;18(3):133-145. doi: 10.2478/abm-2024-0019. eCollection 2024 Jun. Asian Biomed (Res Rev News). 2024. PMID: 39175950 Free PMC article. - The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics.
Tang J, Chen Y, Wang C, Xia Y, Yu T, Tang M, Meng K, Yin L, Yang Y, Shen L, Xing H, Mao X. Tang J, et al. MedComm (2020). 2024 Jul 28;5(8):e663. doi: 10.1002/mco2.663. eCollection 2024 Aug. MedComm (2020). 2024. PMID: 39070181 Free PMC article. Review. - Establishing conditions for the generation and maintenance of estrogen receptor-positive organoid models of breast cancer.
Oliphant MUJ, Akshinthala D, Muthuswamy SK. Oliphant MUJ, et al. Breast Cancer Res. 2024 Mar 29;26(1):56. doi: 10.1186/s13058-024-01798-6. Breast Cancer Res. 2024. PMID: 38553763 Free PMC article. - Experimental and clinical evidence in favour of an effective immune stimulation in ER-positive, endocrine-dependent metastatic breast cancer.
Nicolini A, Rossi G, Ferrari P. Nicolini A, et al. Front Immunol. 2024 Jan 25;14:1225175. doi: 10.3389/fimmu.2023.1225175. eCollection 2023. Front Immunol. 2024. PMID: 38332913 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous